CATX
Perspective Therapeutics Inc.
2.50$
-4.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -484.2% | – | 5,017.4% | -2,739.1% | 912.2% | -11,370.1% | -5,848.8% | -6,880.3% | -7,795.2% | -57,341.9% | -41,405.3% | -25,493.8% | -22,754.8% | |
| 12.4% | – | 129.0% | 176.0% | 181.3% | 308.1% | 198.4% | 252.8% | 370.8% | 2,351.2% | 1,481.6% | 1,408.6% | 991.0% | |
| 21.6% | – | 237.7% | 221.2% | 529.0% | 880.3% | 568.6% | 828.6% | 1,031.6% | 5,369.8% | 3,359.2% | 3,760.5% | 2,460.6% | |
| -26.1% | – | 9,201.4% | 448.9% | 4,427.6% | -4,887.6% | -1,458.8% | -314.8% | 3,488.0% | 1,597.7% | -11,244.7% | 3,177.8% | 490.2% | |
| 10.9% | – | 3,287.0% | 312.3% | 8,052.3% | 6,245.3% | 1,261.8% | 353.8% | 953.1% | 11,802.3% | 9,023.7% | 17,524.7% | 6,875.3% | |
| -10.9% | – | -17,136.6% | -1,013.8% | -8,058.8% | -59,231.6% | -1,508.1% | 1,470.3% | 6,694.7% | 66,365.1% | -144,148.7% | 18,542.0% | -12,715.2% | |
| – | – | – | – | -4.3% | -5.1% | -3.5% | -4.5% | -6.2% | -30.2% | -19.7% | -16.0% | -13.2% | |
| 0.0% | – | 60,263.8% | 37,564.3% | 170.2% | 147.4% | 2,702.7% | 45.5% | 101.9% | -30.2% | 216,268.4% | 181.5% | 40,271.6% | |
| -495.0% | – | 48,144.6% | 33,811.4% | -6,976.4% | -70,454.3% | -4,654.2% | -5,364.5% | -998.6% | 8,993.0% | 30,714.5% | -6,770.4% | 4,801.7% | |
| -495.1% | – | 1,730.4% | -3,051.4% | -7,140.1% | -17,615.4% | -7,110.6% | -7,234.1% | -8,748.3% | -69,144.2% | -50,428.9% | -43,018.5% | -29,630.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.